- Cancer Biology & Biomarkers
- Chromatography & Mass Spectrometry
- Contract Research, Clinical Trials and Outsourcing
- Drug Discovery
- Drug Targets
- Flow Cytometry
- Informatics & Lab Automation
- Ingredients, Excipients and Dosages
- Microbiology & RMMs
- NIR, PAT & QbD
- Raman Spectroscopy
- Screening, Assays & High-Content Analysis
- Thermal Processing
- Events & Workshops
Phase III study to evaluate pemetrexed and pembrolizumab in NSCLC
19 November 2015 • Author: Victoria White
Lilly and Merck are extending their existing collaboration to evaluate the safety and efficacy of the combination of Lilly’s Alimta (pemetrexed for injection) and Merck’s Keytruda (pembrolizumab) in a pivotal Phase III study in first-line non-squamous non-small cell lung cancer (NSCLC).
The study will be open to patients with NSCLC in the first-line setting, regardless of PD-L1 status.
The expansion of this oncology clinical trial collaboration comes following the release of encouraging data from a Phase I study which evaluated pemetrexed, carboplatin and pembrolizumab in first-line non-squamous NSCLC.
Pembrolizumab is a humanised monoclonal antibody that works by increasing the ability of the body’s immune system to help detect and fight tumour cells. Pembrolizumab blocks the interaction between PD-1 and its ligands, PD-L1 and PD-L2, thereby activating T lymphocytes, which may affect both tumour cells and healthy cells – and is currently approved as a single-agent therapy for certain types of NSCLC.
Pemetrexed and pembrolizumab collaboration has ‘great potential’
“The extension of our immuno-oncology collaboration with Merck reinforces our combination-focused strategy, which we believe has the potential to help this patient population where there is a significant unmet need,” said Richard Gaynor, M.D., senior vice president, product development and medical affairs for Lilly Oncology. “Building upon this scientific partnership represents our shared, strong commitment to improve the lives of those living with cancer.”
“Based on the data for Alimta, we believe this collaboration with Lilly has great potential to help even more patients,” said Roger Dansey, M.D., therapeutic area head and senior vice president, oncology late stage development, Merck Research Laboratories. “We look forward to continuing our collaboration with Lilly across all of these trials – including the registrational Phase III all-comers trial for NSCLC.”
In addition to the studies of pemetrexed and pembrolizumab in first-line non-squamous NSCLC, other ongoing trials from the original agreement between Lilly and Merck, through a subsidiary, include a Phase I/II study examining the combination of ramucirumab with pembrolizumab in multiple tumours, and a Phase I/II study examining the combination of necitumumab with pembrolizumab in NSCLC.
ABB Analytical Measurement ACD/Labs ADInstruments Ltd Advanced Analytical Technologies GmbH Analytik Jena AG Astell Scientific Ltd B&W Tek Bachem AG Bibby Scientific Limited Bio-Rad Laboratories BioNavis Ltd Biopharma Group Black Swan Analysis Limited CAPSUGEL NV Charles Ischi AG | Kraemer Elektronik Cherwell Laboratories CI Precision Cobalt Light Systems Coulter Partners CPC Biotech srl Dassault Systèmes BIOVIA DiscoverX Edinburgh Instruments Enterprise System Partners (ESP) Eurofins BioPharma Product Testing EUROGENTEC F.P.S. Food and Pharma Systems Srl GE Analytical Instruments IDBS JEOL Europe L.B. Bohle Maschinen + Verfahren GmbH Lab M Ltd. LabWare Linkam Scientific Instruments Limited MA Business Metrohm Molins Technologies Multicore Dynamics Ltd Nanosurf New England Biolabs, Inc. Ocean Optics Panasonic Biomedical Sales Europe B.V. PerkinElmer Inc ReAgent Russell Finex Limited Source BioScience Takara Clontech Tornado Spectral Systems Tuttnauer Viavi Solutions, Inc Watson-Marlow Fluid Technology Group Wickham Laboratories Limited Xylem Analytics YMC Europe GmbH Yusen Logistics